The shares of medical device maker Impedimed Limited (ASX: IPD) are flying higher today after it announced that its first product for the health and wellness market was available for global pre-order.
In lunchtime trading, shares were up more than 6% at $1.635.
SOZO is the first product on its new population health platform allowing consumers to track everything from their body composition, fluid status, and hydration levels through a variety of settings.
According to the release SOZO is an intuitive digital health device and wellness platform which combines bioimpedance spectroscopy technology with artificial intelligence, creating a rapid, non-invasive scan of a person’s body providing a precise and repeatable snapshot.
Furthermore, predictive analytics in SOZO can access cloud-based historical health data to create a customised plan for the user’s personal health and wellness goals, which it believes will help individuals better manage their health conditions and track their wellness goals.
Managing director and CEO Richard Carreon had this to say on the launch:
“We are fulfilling our vision of population health in the ecosystem of health and wellness. The SOZO platform and our growing pipeline of new and innovative products will position us at the forefront of the digital health revolution. Innovation is at our core and will become the life blood of the organisation. The future is now.”
I like the look of the product and believe that it will be appealing to gyms, personal trainers, athletes, and fitness enthusiasts like myself. There is undoubtedly a growing market for health tracking and as such, I expect the product could do very well.
But I wouldn’t personally recommend making an investment purely on this announcement. Impedimed certainly has a lot going for it at the moment and could well have an exciting future. But until I see pre-order sales figures for SOZO and strong sales growth in its L-Dex lymphoedema detection product, I think I will be sitting this one out.
If there's one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he's staked $209k of our own company money on it. Forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
As of 2.11.2020
Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- ASX 200 up 0.35%: Afterpay & Appen push higher, big four banks rising – January 25, 2021 12:02pm
- Why IDP Education, Lake Resources, Mach7, & Tyro shares are shooting higher – January 25, 2021 11:40am
- Here’s why the Lake Resources (ASX:LKE) share price is rocketing 24% today – January 25, 2021 10:48am